Fonte: Contraception. Unidade: FMRP
Assuntos: SÍNDROME DO OVÁRIO POLICÍSTICO, DISPOSITIVOS ANTICONCEPCIONAIS FEMININOS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEIRA, Carolina Sales et al. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception, v. 86, n. 3, p. 268-275, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.contraception.2011.12.11. Acesso em: 20 set. 2024.APA
Vieira, C. S., Martins, W. de P., Fernandes, J. B. F., Soares, G. M., Reis, R. M. dos, Sá, M. F. S. de, & Ferriani, R. A. (2012). The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception, 86( 3), 268-275. doi:10.1016/j.contraception.2011.12.11NLM
Vieira CS, Martins W de P, Fernandes JBF, Soares GM, Reis RM dos, Sá MFS de, Ferriani RA. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. [Internet]. Contraception. 2012 ; 86( 3): 268-275.[citado 2024 set. 20 ] Available from: https://doi.org/10.1016/j.contraception.2011.12.11Vancouver
Vieira CS, Martins W de P, Fernandes JBF, Soares GM, Reis RM dos, Sá MFS de, Ferriani RA. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. [Internet]. Contraception. 2012 ; 86( 3): 268-275.[citado 2024 set. 20 ] Available from: https://doi.org/10.1016/j.contraception.2011.12.11
